Amgen Planning PGx Study to Gain Full Regulatory Approval for Vectibix in US Market | GenomeWeb

By Turna Ray

Following the accelerated approval of Vectibix in the US in 2006, follow-on studies have failed to show that metastatic colorectal cancer patients on the drug live longer than those receiving standard chemotherapies. However, Amgen this week said it is in the process of conducting a study to try to prove that Vectibix-treated chemorefractory patients whose tumors express the wild-type KRAS gene do survive longer than patients receiving just chemotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.